LEUVEN, Belgium, January 4, 2018 /PRNewswire/ —
Rewind Therapeutics, a privately held Belgian biotech company, today announced the completion of a €15.2 million Series A financing to develop novel re-myelinating therapies for patients suffering from Multiple Sclerosis and other…
